Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma

Jingyu Zhu, Man Wang, Yang Yu, Huixin Qi, Kunkun Han, Juan Tang, Zubin Zhang, Yuanying Zeng, Biyin Cao, Chunhua Qiao, Hongjian Zhang, Tingjun Hou, Xinliang MaoOncotarget 2019 · DOI · OpenAlex

Abstract

This article provides a formal correction to a 2015 study investigating PIK-C98, a novel PI3K inhibitor, as a potential treatment for multiple myeloma (MM). The correction rectifies a figure duplication error in the original publication, providing the accurate Western blot data for AKT expression to confirm the drug's mechanism in triggering programmed cell death (apoptosis). These findings reinforce the potency of PIK-C98 as a targeted therapy for MM.

Introduction

Multiple myeloma (MM) is a complex blood cancer characterized by the malignant proliferation of plasma cells. A key driver in the survival and growth of these cancer cells is the PI3K/AKT/mTOR signaling pathway. When this pathway is overactive, it prevents cancer cells from dying and encourages them to multiply. PIK-C98 is a novel small-molecule inhibitor designed to block PI3K, effectively hitting a "master switch" to induce apoptosis in MM cells.

This specific correction notice was issued because the authors discovered that an image representing AKT expression in Figure 4A was accidentally duplicated from Figure 2A during the final layout of the 2015 paper. Correcting this is vital for maintaining the scientific record and ensuring the preclinical evidence for PIK-C98's efficacy is accurate.

Methods

The researchers utilized several standard molecular biology techniques to validate the effects of PIK-C98. Experiments were performed on a variety of human multiple myeloma cell lines, including JJN3, KMS11, LP1, OCI-My5, OPM2, and RPMI-8226, to ensure the findings were not cell-line specific. Cells were treated with PIK-C98 at varying concentrations (dose-dependent) and for varying lengths of time (time-dependent) to map the kinetics of the drug's action.

Western blotting (immunoblotting) was the primary analytical method, allowing for the visualization of specific proteins. The team specifically looked for markers of apoptosis, such as the cleavage of PARP and Caspase-3, and markers of pathway inhibition, such as phosphorylated AKT (p-AKT) compared to total AKT (t-AKT). GAPDH was used as a loading control to ensure experimental consistency across all lanes.

Key Results and Mechanism

The corrected data reinforces the study's original conclusions regarding the drug's mechanism and broad efficacy.

Targeted Pathway Interruption

The corrected Figure 4A provides the critical evidence for the drug's mechanism: it clearly shows a dose-dependent decrease in p-AKT (Ser473) in JJN3 cells. This proves that PIK-C98 effectively shuts down the PI3K signaling cascade, which is often what keeps myeloma cells "immortal."

Broad-Spectrum Induction of Apoptosis

Figure 4B demonstrates that PIK-C98's pro-apoptotic effect is consistent across six different MM models. Treatment with 20 μM PIK-C98 induced the cleavage of PARP and Caspase-3—the "executioners" of cell death—within 24 hours in all tested cell lines. This suggests the drug might be effective for a wide range of patients regardless of the specific genetic background of their disease.

Figure 4: PIK-C98 activates apoptotic signaling in multiple myeloma cells through AKT inhibition. (A) Dose and time-dependent effects in JJN3 cells. (B) Broad efficacy across a panel of MM cell lines.

Discussion and Conclusion

The time-course data reveals a rapid onset of action, with AKT inhibition and subsequent caspase activation beginning within hours of treatment. While the original publication contained a duplicated image, the underlying experimental data and the resulting conclusions remain unchanged: PIK-C98 is a potent anti-myeloma agent.

As this is a preclinical study, these results were obtained in vitro. Future work would likely involve animal models (xenografts) to see if the drug can reach tumors in a complex biological system. Additionally, future research may explore combination therapies, such as pairing PIK-C98 with proteasome inhibitors like bortezomib, to overcome potential resistance mechanisms. This correction ensures that the foundational evidence for PIK-C98 is accurately represented as it moves toward potential clinical translation.

This article is a summary of the correction notice for DOI: 10.18632/oncotarget.2688.

Summary updated

Abstract

[This corrects the article DOI: 10.18632/oncotarget.2688.].
BibTeX
@inproceedings{zhu2019correction,
  author = {Jingyu Zhu and Man Wang and Yang Yu and Huixin Qi and Kunkun Han and Juan Tang and Zubin Zhang and Yuanying Zeng and Biyin Cao and Chunhua Qiao and Hongjian Zhang and Tingjun Hou and Xinliang Mao},
  title = {{Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma}},
  booktitle = {Oncotarget},
  year = {2019},
  doi = {10.18632/oncotarget.27350},
}

Loading related content...

Figure